ScripThe timely and cost-efficient manufacturing of cell and gene therapies is expected to be key to their commercial success, and Catalent Inc. ’s acquisition of MaSTherCell SA indicates a desire to bu
Pink SheetJapan is seen as having possibly the most positive research and policy environment for gene and cell therapies globally, which can be traced back largely to reforms enacted in the wake of the 2012 Nob
Medtech InsightFujifilm Holdings Corp. is flexing its muscles in the diagnostic imaging space with a billion-dollar acquisition of Hitachi Ltd. 's diagnostic imaging business. The two Japanese companies announced
In VivoIn 2019, attention-grabbing headlines such as Roche ’s acquisition of Spark Therapeutics Inc. for $4.8bn, Biogen Inc. ’s $877m play for Nightstar Therapeutics PLC , and Vertex Pharmaceuticals In